Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.34 |
| ▸ | IL1B | P01584 | 3/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3027397 | 0.90 | ALDH1A1 (0.42) | LMNASMN1; SMN2GPBAR1KMT2AALDH1A1 | |
| SCHEMBL8672508 | 0.82 | GPBAR1 (0.37) | LMNAGPBAR1KMT2AALDH1A1KDM4E | |
| SCHEMBL4755336 | 0.76 | LMNA (0.42) | LMNASMN1; SMN2KMT2AALDH1A1KDM4E | |
| SCHEMBL4757355 | 0.75 | PYGM (0.39) | LMNAALDH1A1GAA | |
| SCHEMBL4755356 | 0.75 | TSHR (0.37) | LMNASMN1; SMN2KMT2AALDH1A1KDM4E | |
| SCHEMBL10951083 | 0.75 | MAOB (0.44) | KMT2AKDM4EATMMAPT | |
| SCHEMBL11125337 | 0.72 | LMNA (0.34) | LMNASMN1; SMN2KMT2AALDH1A1KDM4E | |
| SCHEMBL4755325 | 0.71 | ALDH1A1 (0.37) | LMNAGPBAR1KMT2AALDH1A1GAA | |
| SCHEMBL6951541 | 0.70 | LMNA (0.36) | LMNASMN1; SMN2KMT2AALDH1A1GAA | |
| SCHEMBL4732866 | 0.69 | NR3C2 (0.33) | LMNASMN1; SMN2GPBAR1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185130-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ROSKAMP RESEARCH LLC | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185130-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | LMNA 935/4885SMN1; SMN2 2187/4885GPBAR1 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.